email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
346 - 360
of 3630 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
Next
Fosun Kite Approved to Launch CAR-T as Second Line Therapy for B-Cell Lymphoma
$5.00
Available
Antengene Doses First Patient in Trial of ERK1/2 Inhibitor Combined with BMS’s PD-1
$5.00
Available
HighField Biopharma Starts China Trial of Immune Modulating Liposome for Glioma
$5.00
Available
Kelun-Biotech Raises $174 Million in Hong Kong IPO for ADC Portfolio
$5.00
Available
GeneQuantum Licenses Novel Bioconjugation Technology to InxMed
$5.00
Available
Beijing InnoCare Plans Combined Therapy with Arrivent for NSCLC
$5.00
Available
Connect Reports Progress in Next-gen IL-4Rα Antibody for Atopic Dermatitis
$5.00
Available
GeneQuantum Adds Five ADC Candidates to its Collaboration with Aimed, a Korean Biotech
$5.00
Available
Fosun Pharma Files China NDA for Hyperphosphatemia Therapy in Dialysis Patients
$5.00
Available
Biosyngen to Establish Guangzhou-Singapore Translational Center for Cancer Drugs
$5.00
Available
Sinotau Pharma Completes $152 Million E Round for Radiopharmaceutical Portfolio
$5.00
Available
280Bio, a Yingli Pharma Subsidiary, to Start US Trials of RAS Inhibitor
$5.00
Available
BeiGene Options ADC for Solid Tumor Cancer from Duality Bio in $1.3 Billion Deal
$5.00
Available
WuXi Biologics Plans Spin-off and $500 Million Hong Kong IPO of Conjugates Subsidiary
$5.00
Available
Sirnaomics Provides Capital and RNA Delivery Technology to EDIRNA, an RNA Editing Company
$5.00
Available